Education
About Us
Working with TipRanks
Follow Us
NOXXON Pharma NV (FR:ALTME)
:ALTME
ALTME Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.06 - €0.19
Previous CloseN/A
Volume26.06K
Average Volume (3M)609.23K
Market Cap
€7.62M
Enterprise ValueN/A
Total Cash (Recent Filing)€2.70M
Total Debt (Recent Filing)€5.00K
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Oct 17, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding94,186,550
10 Day Avg. Volume764,001
30 Day Avg. Volume609,227
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ALTME FAQ
What was NOXXON Pharma NV’s price range in the past 12 months?
NOXXON Pharma NV lowest stock price was €0.06 and its highest was €0.19 in the past 12 months.
What is NOXXON Pharma NV’s market cap?
NOXXON Pharma NV’s market cap is €7.62M.
When is NOXXON Pharma NV’s upcoming earnings report date?
NOXXON Pharma NV’s upcoming earnings report date is Oct 17, 2025 which is in 147 days.
How were NOXXON Pharma NV’s earnings last quarter?
NOXXON Pharma NV released its earnings results on Apr 25, 2025. The company reported -€0.026 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.026.
Is NOXXON Pharma NV overvalued?
According to Wall Street analysts NOXXON Pharma NV’s price is currently Overvalued.
Does NOXXON Pharma NV pay dividends?
NOXXON Pharma NV does not currently pay dividends.
What is NOXXON Pharma NV’s EPS estimate?
NOXXON Pharma NV’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NOXXON Pharma NV have?
NOXXON Pharma NV has 94,186,550 shares outstanding.
What happened to NOXXON Pharma NV’s price movement after its last earnings report?
NOXXON Pharma NV reported an EPS of -€0.026 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NOXXON Pharma NV?
Currently, no hedge funds are holding shares in FR:ALTME
Company Description
NOXXON Pharma NV
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck Sharp & Dohme Corp. to study NOX-A12 combined with Keytruda and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is based in Berlin, Germany.